石藥集團(01093.HK)司庫奇尤單抗注射液臨床試驗獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

石藥集團(01093.HK)司庫奇尤單抗注射液臨床試驗獲批

阿思達克 11-02 03:26

石藥集團(01093.HK)公布，集團開發的司庫奇尤單抗注射液已獲中國國家藥品監督管理局批准，可於內地開展臨床研究。該產品是人白介素-17A全人源單克隆抗體，為可善挺的生物類似藥，適用於治療符合系統治療或光療指證的中度至重度斑塊狀銀屑病的成年患者。

石藥集團(01093.HK)

Relevant Stocks

石藥集團(01093.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

石藥集團(01093.HK)司庫奇尤單抗注射液臨床試驗獲批

Services

About Us

Agreement Statement